ESMO 2018 | SOLAR-1: alpelisib plus fulvestrant for advanced breast cancer

Fabrice André

The latest from SOLAR-1 (NCT02437318), assessing alpelisib plus fulvestrant for advanced breast cancer that progressed on or after aromatase inhibitor treatment., is presented by Fabrice André, MD, PhD, of the Gustave Roussy Institute, Villejuif, France, here at the breast cancer press briefing at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, which showcased the latest updates for three major Phase III clinical trials.

Share this video